Observational analysis shows no difference in predictive power for molecular recurrence in CML patients, suggesting reliance on peripheral blood measurements instead.
Key Points
Predictive power for TFR success was similar between bone marrow and peripheral blood measurements.
Log10[BCR::ABL1[IS]] values from bone marrow had an odds ratio of 1.8, while those from peripheral blood had an odds ratio of 2.6.
Patients categorized as low-risk showed an 87% molecular recurrence-free survival at 24 months, highlighting the importance of risk classification.
In this analysis, sequential BCR::ABL1 kinetics from peripheral blood improved risk prediction during TKI de-escalation.